Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Proteostasis Therapeutics Inc (NASDAQ:PTI)

2.26
Delayed Data
As of Oct 18
 +0.12 / +5.61%
Today’s Change
1.71
Today|||52-Week Range
16.67
-81.57%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$53.7M

Company Description

Proteostasis Therapeutics, Inc. engages in the research, development, and market of pharmaceutical products. Its medicines intend to treat cystic fibrosis, protein conformational and neurodegenerative diseases. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Cambridge, MA.

Contact Information

Proteostasis Therapeutics, Inc.
200 Technology Square
Cambridge Massachusetts 02139
P:(617) 225-0096
Investor Relations:

Employees

Shareholders

Individual stakeholders68.64%
Other institutional36.51%
Mutual fund holders21.42%

Top Executives

Meenu Chhabra KarsonPresident, Chief Executive Officer & Director
Helen M. BoudreauChief Financial Officer & Treasurer
Benito MunozChief Scientific Officer
Po-Shun LeeChief Medical Officer & Executive Vice President
Sheila WilsonVice President-Clinical Operations